Wuxi Biologics (Cayman) Inc. (HK:2269)
:2269
Want to see HK:2269 full AI Analyst Report?
Total Valuation
Wuxi Biologics (Cayman) has a market cap or net worth of HK$135.24B. The enterprise value is HK$111.13B.
Market CapHK$135.24B
Enterprise ValueHK$111.13B
Share Statistics
Wuxi Biologics (Cayman) has 4,140,823,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,140,823,700
Owned by Insiders―
Owned by Institutions0.02%
Financial Efficiency
Wuxi Biologics (Cayman)’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 9.03%.
Return on Equity (ROE)0.10
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)9.03%
Return on Capital Employed (ROCE)0.12
Revenue Per Employee1.69M
Profits Per Employee380.22K
Employee Count12,575
Asset Turnover0.33
Inventory Turnover7.96
Valuation Ratios
The current PE Ratio of Wuxi Biologics (Cayman) is 11.1. Wuxi Biologics (Cayman)’s PEG ratio is 0.53.
PE Ratio11.1
PS Ratio5.36
PB Ratio2.41
Price to Fair Value2.41
Price to FCF40.64
Price to Operating Cash Flow17.62
PEG Ratio0.53
Income Statement
In the last 12 months, Wuxi Biologics (Cayman) had revenue of 21.23B and earned 4.78B in profits. Earnings per share was 1.19.
Revenue21.23B
Gross Profit9.76B
Operating Income6.47B
Pretax Income7.07B
Net Income4.78B
EBITDA8.17B
Earnings Per Share (EPS)1.19
Cash Flow
In the last 12 months, operating cash flow was 6.41B and capital expenditures -3.71B, giving a free cash flow of 2.70B billion.
Operating Cash Flow6.41B
Free Cash Flow2.70B
Free Cash Flow per Share0.65
Dividends & Yields
Wuxi Biologics (Cayman) pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.81
52-Week Price Change40.47%
50-Day Moving Average36.52
200-Day Moving Average34.46
Relative Strength Index (RSI)51.10
Average Volume (3m)32.67M
Important Dates
Wuxi Biologics (Cayman) upcoming earnings date is Aug 24, 2026, TBA (Confirmed).
Last Earnings DateMar 24, 2026
Next Earnings DateAug 24, 2026
Ex-Dividend Date―
Financial Position
Wuxi Biologics (Cayman) as a current ratio of 3.14, with Debt / Equity ratio of 6.57%
Current Ratio3.14
Quick Ratio2.97
Debt to Market Cap0.01
Net Debt to EBITDA-0.75
Interest Coverage Ratio46.46
Taxes
In the past 12 months, Wuxi Biologics (Cayman) has paid 1.48B in taxes.
Income Tax1.48B
Effective Tax Rate0.21
Enterprise Valuation
Wuxi Biologics (Cayman) EV to EBITDA ratio is 13.17, with an EV/FCF ratio of 38.45.
EV to Sales5.07
EV to EBITDA13.17
EV to Free Cash Flow38.45
EV to Operating Cash Flow16.85
Balance Sheet
Wuxi Biologics (Cayman) has HK$15.74B in cash and marketable securities with HK$3.11B in debt, giving a net cash position of HK$12.64B billion.
Cash & Marketable SecuritiesHK$15.74B
Total DebtHK$3.11B
Net CashHK$12.64B
Net Cash Per ShareHK$3.05
Tangible Book Value Per ShareHK$12.68
Margins
Gross margin is 45.95%, with operating margin of 30.50%, and net profit margin of 22.53%.
Gross Margin45.95%
Operating Margin30.50%
Pretax Margin33.30%
Net Profit Margin22.53%
EBITDA Margin38.49%
EBIT Margin30.50%
Analyst Forecast
The average price target for Wuxi Biologics (Cayman) is HK$46.01, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$46.01
Price Target Upside28.81% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast16.79%
EPS Growth Forecast47.14%